Loading...
XSHE300759
Market cap12bUSD
Dec 25, Last price  
27.09CNY
1D
0.66%
1Q
26.49%
IPO
127.12%
Name

Pharmaron Beijing Co Ltd

Chart & Performance

D1W1MN
XSHE:300759 chart
P/E
56.37
P/S
7.82
EPS
0.48
Div Yield, %
0.49%
Shrs. gr., 5y
14.91%
Rev. gr., 5y
31.74%
Revenues
11.54b
+12.39%
790,440,0471,128,037,5581,634,238,6802,294,118,0662,908,123,0333,757,160,0865,133,596,7587,443,769,72410,266,288,17911,537,996,314
Net income
1.60b
+16.48%
20,995,24073,846,442176,911,924230,857,087339,224,479547,191,4861,172,382,3871,661,028,5671,374,604,2241,601,096,033
CFO
2.75b
+28.50%
12,134,600216,939,062235,767,733552,215,324737,258,351938,586,3211,648,609,9572,058,043,8302,142,816,4162,753,538,934
Dividend
Jun 27, 20240.2 CNY/sh
Earnings
Jun 06, 2025

Profile

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
URL
https://www.pharmaron.cn/
IPO date
Jan 28, 2019
Employees
19,733
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
11,537,996
12.39%
10,266,288
37.92%
7,443,770
45.00%
Cost of revenue
8,866,701
7,749,700
5,327,068
Unusual Expense (Income)
NOPBT
2,671,295
2,516,588
2,116,702
NOPBT Margin
23.15%
24.51%
28.44%
Operating Taxes
256,106
314,254
290,919
Tax Rate
9.59%
12.49%
13.74%
NOPAT
2,415,189
2,202,334
1,825,783
Net income
1,601,096
16.48%
1,374,604
-17.24%
1,661,029
41.68%
Dividends
(444,792)
(404,761)
(284,715)
Dividend yield
0.86%
0.75%
0.44%
Proceeds from repurchase of equity
(830)
(1)
BB yield
0.00%
0.00%
Debt
Debt current
577,071
901,747
577,593
Long-term debt
9,370,060
5,975,290
4,991,860
Deferred revenue
152,375
149,439
Other long-term liabilities
799,328
112,093
81,559
Net debt
2,843,882
4,371,241
471,013
Cash flow
Cash from operating activities
2,753,539
2,142,816
2,058,044
CAPEX
(2,865,321)
Cash from investing activities
(2,250,833)
Cash from financing activities
3,915,262
3,661,395
FCF
697,679
(557,902)
(1,007,206)
Balance
Cash
6,720,255
2,242,846
5,098,441
Long term investments
382,994
262,950
Excess cash
6,526,350
1,992,482
4,726,252
Stockholders' equity
7,673,156
5,832,119
4,256,172
Invested Capital
16,872,959
15,040,089
11,441,058
ROIC
15.14%
16.63%
19.33%
ROCE
11.42%
14.55%
13.34%
EV
Common stock shares outstanding
1,775,248
1,184,187
1,213,227
Price
28.98
-36.07%
45.33
-15.22%
53.47
-55.59%
Market cap
51,446,683
-4.16%
53,679,195
-17.25%
64,871,227
-54.71%
EV
54,971,813
58,341,688
65,508,306
EBITDA
3,598,466
3,212,768
2,614,622
EV/EBITDA
15.28
18.16
25.05
Interest
182,192
167,312
83,073
Interest/NOPBT
6.82%
6.65%
3.92%